Alnylam Pharmaceuticals, Inc. (ALNY) News
Filter ALNY News Items
ALNY News Results
|Loading, please wait...|
ALNY News Highlights
- For ALNY, its 30 day story count is now at 75.
- Over the past 28 days, the trend for ALNY's stories per day has been choppy and unclear. It has oscillated between 1 and 22.
- DRUG, RNA and NVS are the most mentioned tickers in articles about ALNY.
Latest ALNY News From Around the Web
Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.
Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors
WATERTOWN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR ), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of John Maraganore, Ph.D. to its Board of Directors. Dr. Maraganore joins Kymera''s Board after having led Alnylam Pharmaceuticals as founding CEO and Director and transformed the field of RNA therapeutics for the last nearly 20 years. "John has been a true pioneer and an inspiration for the whole biotech industry. As founding CEO of Alnylam, he has built one of the most successful biotech companies, evolving RNA therapeutics into a commercial stage therapeutic reality for patients around the globe." said Nello Mainolfi, P...
Former Alnylam Pharmaceuticals CEO John Maraganore, considered a pioneer of RNA therapeutics, has joined the board of Kymera Therapeutics.
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
CAMBRIDGE, Mass., January 14, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 18-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, at the Société Francophone du Nerf Périphérique (SFNP) Annual Meeting. The meeting will be held January 21-22 in Pa
No summary available.
In a report released today, Gary Nachman from BMO Capital maintained a Hold rating on Alnylam Pharma (ALNY – Research Report), with a price target of $180.00. The company's shares closed last Tuesday at $146.96. According to TipRanks.com, Nachman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.4% and a 40.7% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Pacira Pharmaceuticals, and Ionis Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $215.35 average price target, which is a 42.
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) said that it expects its full year 2021 non-GAAP operating loss to be substantially improved relative to the prior year. As of on December 31, 2021, Alnylam had preliminary cash, cash equivalents, and marketable securities of about $2.4 billion, compared to $1.9 billion at December 31, 2020.
(Bloomberg) -- Yvonne Greenstreet was sitting on a plane at Boston Logan International Airport waiting to take off in 2018 when U.S. regulators approved Alnylam Pharmaceuticals Inc.’s first drug, Onpattro. The chief operating officer grabbed her carry-on from the overhead bin, ran off the plane and bolted to the office so she could celebrate the accomplishment with her colleagues. Most Read from BloombergCypriot Scientist Says Deltacron Covid Variant Isn’t ErrorWorld’s Biggest Crypto Fortune Beg
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
CAMBRIDGE, Mass., January 09, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2021 global net product revenues for ONPATTRO, GIVLAARI and OXLUMO and provided additional updates on the products’ commercial launches.
Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.
Here's why you'll want to keep both eyes open for upcoming announcements from Alnylam Pharmaceuticals (NASDAQ: ALNY), Intercept Pharmaceuticals (NASDAQ: ICPT), and Karuna Therapeutics (NASDAQ: KRTX). Shares of Alnylam recently slipped around 15% overnight in response to a surprising clinical-trial flop for a drug it isn't even developing. Recently, BridgeBio Pharma told investors that people with heart damage caused by transthyretin amyloidosis (ATTR) who received acoramidis failed to outperform the placebo group on the six-minute walking test.